Fatty Liver Index (FLI) Identifies Not Only Individuals with Liver Steatosis but Also at High Cardiometabolic Risk
International Journal of Molecular Sciences · 27.09.2023 · 24 (19) · 14651
DOI: 10.3390/ijms241914651 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 27.09.2023. Verfasst von Fabrizia Carli und 5 weiteren Autor:innen. Beteiligte Einrichtung: Cardiometabolic Risk Unit, Institute of Clinical Physiology, National Research Council (CNR), Via Giuseppe Moruzzi, 1, 56124 Pisa, Italy. Hauptthemen laut MEDLINE: Metabolic Syndrome, Fatty Liver, Insulin Resistance, Cardiovascular Diseases. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: EFSD European Foundation for teh Study of Diabetes, European Council, National Research Council - CNR.
Abstract (Originalsprache)
A fatty liver index (FLI) greater than sixty (FLI ≥ 60) is an established score for metabolic dysfunction-associated steatotic liver disease (MASLD), which carries a high risk for diabetes and cardiovascular disease, while a FLI ≤ 20 rules out the presence of steatosis. Thus, we investigated whether FLI was associated with cardiometabolic risk factors, i.e., visceral (VAT), subcutaneous (SC), epicardial (EPI), extrapericardial (PERI), and total cardiac (CARD-AT) adipose tissue, hepatic fat ((by magnetic resonance imaging, MRI, and spectroscopy, MRS), and insulin resistance (IR, HOMA-IR and OGIS-index), and components of metabolic syndrome. All individuals with FLI ≥ 60 had MASLD, while none with FLI ≤ 20 had steatosis (by MRS). Subjects with FLI ≥ 60 had a higher BMI and visceral and cardiac fat (VAT > 1.7 kg, CARD-AT > 0.2 kg). FLI was positively associated with increased cardiac and visceral fat and components of metabolic syndrome. FLI, VAT, and CARD-AT were all associated with IR, increased blood pressure, cholesterol, and reduced HDL. For FLI ≥ 60, the cut-off values for fat depots and laboratory measures were estimated. In conclusion, FLI ≥ 60 identified not only subjects with steatosis but also those with IR, abdominal and cardiac fat accumulation, increased blood pressure, and hyperlipidemia, i.e., those at higher risk of cardiometabolic diseases. Targeted reduction of FLI components would help reduce cardiometabolic risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cardiometabolic Risk Unit, Institute of Clinical Physiology, National Research Council (CNR), Via Giuseppe Moruzzi, 1, 56124 Pisa, Italy.
- Department of Medical and Surgical Sciences, University of Bologna, Via Zamboni, 33, 40126 Bologna, Italy.
ORCID-Profile: Fabrizia Carli, Silvia Sabatini, Anna Maria Sironi, Giorgio Bedogni, Amalia Gastaldelli
Förderung
- EFSD European Foundation for teh Study of Diabetes
- European Council
- National Research Council - CNR
- EFSD-Pfizer program
- EU-H2020 Program
- National Research Council—CNR
Zitieren
APA
Carli, F., Sabatini, S., Gaggini, M., Sironi, A. M., Bedogni, G., & Gastaldelli, A. (2023). Fatty Liver Index (FLI) Identifies Not Only Individuals with Liver Steatosis but Also at High Cardiometabolic Risk. International Journal of Molecular Sciences, 24(19), 14651. https://doi.org/10.3390/ijms241914651
Vancouver
Carli F, Sabatini S, Gaggini M, Sironi AM, Bedogni G, Gastaldelli A. Fatty Liver Index (FLI) Identifies Not Only Individuals with Liver Steatosis but Also at High Cardiometabolic Risk. International Journal of Molecular Sciences. 2023;24(19):14651. doi:10.3390/ijms241914651
BibTeX
@article{Carli2023,
author = {Carli, Fabrizia and Sabatini, Silvia and Gaggini, Melania and Sironi, Anna Maria and Bedogni, Giorgio and Gastaldelli, Amalia},
title = {Fatty Liver Index (FLI) Identifies Not Only Individuals with Liver Steatosis but Also at High Cardiometabolic Risk},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {19},
pages = {14651},
doi = {10.3390/ijms241914651}
}
EUVIMED